You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Differences In Outcomes Of Patients With Congestive Heart Failure Prescribed Celecoxib, Rofecoxib, Or Non-Steroidal Anti-Inflammatory Drugs: Population Based Study
Marie Hudson, Hugues Richard and Louise Pilote
BMJ: British Medical Journal
Vol. 330, No. 7504 (Jun. 11, 2005), pp. 1370-1373
Published by: BMJ
Stable URL: http://www.jstor.org/stable/25459904
Page Count: 4
You can always find the topics here!Topics: Congestive heart failure, Disease risks, Nonsteroidal antiinflammatory agents, Older adults, Hospital admissions, Health outcomes, Databases, Antiinflammatories, Heart, Drug prescriptions
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Objectives To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. Design Population based retrospective cohort study. Setting Databases of hospital discharge summaries and prescription drug claims in Quebec. Participants 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or a NSAID after an index admission for congestive heart failure between April 2000 and March 2002. Main outcome measures Time to all cause death and recurrent congestive heart failure, combined and separately. Results The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib. Conclusions Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.
BMJ: British Medical Journal © 2005 BMJ